Estrogen-only therapy linked to reduced Alzheimer's brain pathology in women

A new study published on August 12, 2026, in the journal Neurology has found that women who used estrogen-only hormone therapy after menopause showed fewer biological signs of Alzheimer's disease in their brains after death. The research, conducted by a team at Stanford University, analyzed data from over 21,000 women and suggests a potential protective association between this specific hormone therapy and reduced Alzheimer's pathology, though experts caution the findings do not prove the therapy prevents the disease.

The study examined two large Alzheimer's datasets, focusing on women who reported using systemic estrogen-only therapy. A key component involved analyzing brain autopsies from nearly 3,000 women. After adjusting for factors such as age, race, education, and genetic predisposition, researchers found that women who had used estrogen-only therapy had 35 percent lower odds of having severe Alzheimer's-related changes in their brains, including amyloid plaques and tau tangles. The therapy was also linked to a 39 percent lower risk of a clinical dementia diagnosis and a 33 percent lower likelihood of memory or functional decline.

The findings are particularly significant...